Peroxisome proliferator-activated receptors α, γ agonists and tumors / 国际药学研究杂志

ABSTRACT

Peroxisome proliferator-activated receptors (PPAR) are members of the nuclear hormone receptor superfamily. So far, three PPAR isotypes (PPARα, PPARβ/δ and PPARγ) have been identified, PPARα and PPARγ agonists have been used in clinic for treatment of hyperlipidemia and diabetes mellitus, respectively. Meanwhile, candidates targeting PPARβ/δ have entered the clinical study. However, some pre-clinical and clinical studies have indicated that some agonists of PPARα/γ and PPARβ/δ can induce various tumors in mice, and PPARγ agonist pioglitazone may enhance the bladder cancer risk in humans. Therefore, the role of PPAR agonists in tumorigenesis has aroused much attention. This review mainly focuses on the progress in PPARα and PPARγ agonists in tumors, aiming to provide more information for the safe medication and further development of PPAR agonists.